dfds-logo-2021-group-blue-rgb.png
INVITATION TO CONFERENCE CALL FOR DFDS’ REPORT FOR Q4 2022
January 30, 2023 04:45 ET | DFDS A/S
INVESTOR NEWS no. 02 - 30 January 2023  DFDS expects to publish the report for Q4 2022 on 9 February 2023 at around 07:30 CET. Torben Carlsen, CEO, and Karina Deacon, CFO, will present the report...
INVITATION TO CONFERENCE CALL FOR DFDS’ REPORT FOR Q4 2022
January 30, 2023 04:45 ET | DFDS A/S
INVESTOR NEWS no. 02 - 30 January 2023  DFDS expects to publish the report for Q4 2022 on 9 February 2023 at around 07:30 CET. Torben Carlsen, CEO, and Karina Deacon, CFO, will present the...
INVITATION TIL TELE-KONFERENCE OM DFDS’ RAPPORT FOR 4. KVT. 2022
January 30, 2023 04:45 ET | DFDS A/S
INVESTOR NEWS nr. 02 - 30. januar 2023  DFDS’ kvartalsrapport for 4. kvt. 2022 forventes offentliggjort 9. februar 2023 omkring kl. 07.30. Rapporten præsenteres på en tele-konference af...
CoinShares_Logo.png
CoinShares Announces Preliminary Full-Year Results for the period ended 31 December 2021
February 22, 2022 03:00 ET | CoinShares International Limited
CoinShares delivers strongest full-year & fourth quarter financial results in the Group’s history 22 February 2022 | SAINT HELIER, Jersey | CoinShares International Limited (Nasdaq...
Q4 INTERIM AND FULL-YEAR 2021 REPORT
February 08, 2022 01:52 ET | DFDS A/S
COMPANY ANNOUNCEMENT NO. 5/2022 GROWTH SET TO CONTINUE IN 2022 EBITDA increased 19% to DKK 915m in Q4Supply chain bottlenecks eased during Q4Early signs of pick-up in passenger...
DELÅRSRAPPORT FOR 4. KVT 2021 OG HELE ÅRET
February 08, 2022 01:52 ET | DFDS A/S
SELSKABSMEDDELELSE NR. 5/2022 KLAR TIL FORTSAT VÆKST I 2022 EBITDA steg 19% til DKK 915 mio. i 4. kvartalFlaskehalse i forsyningskæder lettede i kvartaletFørste tegn på vækst i...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Announces Full Year 2019 Financial Results and Corporate Update
March 31, 2020 06:42 ET | BioNTech SE
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT122 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020COVID-19 vaccine program BNT162 set to enter the clinic in April...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech veröffentlicht Ergebnisse des gesamten Geschäftsjahres 2019 sowie Informationen zur Geschäftsentwicklung
March 31, 2020 06:42 ET | BioNTech SE
Zulassungsstudie mit BNT111 FixVac bei Hautkrebs soll in der zweiten Jahreshälfte 2020 beginnen  Phase-2-Studie mit BNT122 (iNeST) als adjuvante Behandlung in NSCLC soll in der zweiten...
p5c92dd987fc0c40004d9806b_1.png
Progressive Care Reports November Performance: Q4 Maintains Record Pace, Net Profitable for Consecutive Months
December 17, 2019 08:00 ET | Progressive Care, Inc.
MIAMI, FL, Dec. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company,...